Project Grant R44EY038121
Award Date 9/30/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72207, USA
Similar Awards
- This $588,731 federal Project Grant was awarded on March 1, 2025 by the National Eye Institute (NEI) under the Vision Research grant program (CFDA 93.867) to The University of Iowa. The funding supports research to investigate the role of ferroptosis, a novel form of cell death, in the development and progression of Fuchs Endothelial Corneal Dystrophy (FECD), a leading cause of corneal transplantation in the United States. The researchers aim to develop a preventive medical therapy, such as...
- This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $330,169 to ESK Therapeutics, Inc. to commercialize a biologic eyedrop formulation called CornealClear for the treatment of persistent corneal epithelial defects (PCED). The project aims to demonstrate that the CornealClear eyedrops can accelerate corneal wound healing and reduce scarring in a rabbit model, as well as confirm the systemic safety of the prolactin-induced protein (PIP) formulation. If...
- This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) is supporting research at New York University (NYU) to investigate the mechanism of corneal lens development in the Drosophila model organism. The $142,749 award, spanning September 2025 to August 2027, aims to use genetic, microscopy, and transcriptomic approaches to study the role of the polysaccharide chitin and the central and lattice cells of the fly corneal lens in...
- This federal Project Grant award of $306,118 was provided by the National Eye Institute (CFDA 93.867 - Vision Research) to Eyescreen, Inc. for the project "DRUG SCREENING PLATFORM IN THE LIGHT-RESPONSIVE HUMAN EYE". The goal of this award is to develop new technology and assays to test the efficacy and safety of investigational new drugs (INDs) for blinding diseases like age-related macular degeneration, diabetic retinopathy, glaucoma, and inherited retinal degenerations using...
- This $348,800 Project Grant was awarded on September 30, 2025 by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), to N'Waii Inc. in Chicago, Illinois. The grant supports the development of a first-in-class mitochondrially targeted antioxidant drug candidate for the treatment of dry eye disease (DED), a condition affecting 20% of the global adult population. The drug candidate exhibits potent free radical scavenging capabilities and has demonstrated...
- The National Eye Institute (NEI) awarded a $482,067 Project Grant to Washington State University (WSU) on August 1, 2025 under the Vision Research federal grant program (CFDA 93.867). The grant supports research to develop novel nanotherapies for the targeted treatment of corneal neovascularization, a sight-threatening condition characterized by the growth of blood vessels into the cornea. The funding will enable WSU researchers to synthesize a unique trehalose-based dendrimer (TRE-D) that...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $321,904 Project Grant to Proteris Biotech, Inc. through the Vision Research federal grant program (CFDA 93.867). The award, spanning August 1, 2025 to July 31, 2026, will fund the early development of the natural tear protein clusterin (CLU) as a novel approach to treat dry eye disease. The research aims to conduct non-GMP stability analysis of the drug substance and product, as well as perform...
- This federal Project Grant award of $243,000 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to understand the role of the protein SMAD4 in regulating the extracellular matrix homeostasis of the corneal stroma. The research aims to elucidate how SMAD4 controls both the synthesis and degradation of the corneal extracellular matrix, which is critical for corneal stromal morphogenesis and homeostasis. The project, led by researchers at the...
- This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...